RxDoctor Payments Data

Doreen Ho, MD

Neurology · Burlington, MANPI 1720295124

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,381 of the $10,632 with a category attached, or 97.6%. Sanofi accounts for 78.0% of it on its own, with 2 other manufacturers making up the rest.

$10,632in general payments, 2019–2025

Across 5 payments — averaging $2126.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$8K
  • Biogen$2K
  • Genentech, Inc.$129
$300,180in research payments, 2019–2025

Across 50 payments — averaging $6003.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$187K
  • AbbVie$43K
  • AstraZeneca$31K
  • Genentech, Inc.$25K
  • Mitsubishi Tanabe Pharma Development America, Inc.$14K

What the payments were for

  • Consulting fees$10,38198%
  • Food & beverage$1892%
  • Education$631%

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi2$8,295
Biogen2$2,209
Genentech, Inc.1$129

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,632 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$34,661
Medicare patients
107
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone224$3,215,485
EvrysdiRisdiplam71$1,968,214
RelyvrioSod Phenylbutyrat/Taurursodiol33$412,756
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$104,691
NuedextaDextromethorphan Hbr/Quinidine33$69,815
Riluzole124$20,821
Glycopyrrolate21$5,266
Atropine Sulfate22$782
Insulin SyringeSyringe And Needle,insulin,1ml11$675
Baclofen26$339
Citalopram HbrCitalopram Hydrobromide19$127
Pregabalin18$110
Lorazepam28$60

Paid to pharmacies, not to this prescriber.

Other neurology in Burlington

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →